Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.SLRX · Entity 937 | Director | March 23, 2020 | March 25, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date March 23, 2020 · Filed March 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2030-03-22 | Direct | 6,000 |
Reported balance
After 2020-03-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-23 · Grant · Acquired 6,000 · Balance 6,000 F1: Options granted are fully vested on March 23, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted are fully vested on March 23, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2020 Filed Mar 25, 2020 22:04 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001615219-20-000031 · wf-form4_158517386437979.xml · derivative · entry 1 Northrup Jonathan P · CIK 0001770559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2030-03-22 F1 · derivative.exercise_date: Options granted are fully vested on March 23, 2021. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 02:34 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 8,700 | $1.15 | $10,005.00 |
DisclosureSEC source: 0000899243-20-004420 · doc4.xml · nonDerivative · entry 1 Northrup Jonathan P · CIK 0001770559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,713 Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 02:06 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseWarrants (right to buy) · Derivative | 8,700 | $0.01 Strike: $1.15 | $87.00 |
DisclosureSEC source: 0000899243-20-004566 · doc4.xml · derivative · entry 1 Northrup Jonathan P · CIK 0001770559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Common Stock · 8,700 shares Expires 2025-02-11 F1 · security: The Reporting Person acquired these securities in the Issuer's public offering of Class A Units on February 11, 2020. Each Class A Unit consisted of one share of Common Stock and one warrant to purchase a single share of Common Stock. Read SEC document |
| September 10, 2019 Filed Sep 13, 2019 10:16 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001615219-19-000037 · wf-form4_156836975523831.xml · derivative · entry 1 Northrup Jonathan P · CIK 0001770559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2029-09-10 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.